Medidata vs Octozi (2026)
The incumbent platform against the specialist in clinical data operations. Medidata's capabilities sit on a trial platform spanning tens of thousands of studies with the most complete security disclosure in this index, so for a sponsor already running it the AI arrives inside an environment that is already validated. Octozi automates the data cleaning, reconciliation, review and reporting that determines whether a submission lands on time, describes its architecture concretely as language models paired with deterministic clinical algorithms, and published a controlled study with named reviewers. The validation burden usually decides this: adding capability inside a qualified system is a far shorter path than qualifying a new one. Where Octozi wins is that it published what it does and how well, and Medidata names its capabilities without describing them.
- The capabilities sit on a clinical trial platform spanning tens of thousands of studies and millions of patients, which is the asset the AI is built on.
- The security disclosure for the underlying platform is the most complete located anywhere in this index.
- For a sponsor already running the platform, adding capability inside a validated environment avoids the revalidation questions a new system triggers.
- The architecture is described concretely, combining language models with deterministic clinical algorithms rather than relying on generation, with human in the loop stated as an architectural commitment.
- A published controlled study with named reviewers reports throughput results, which is more evidence than most vendors at this stage produce.
- It targets the data operations layer where submission timelines actually slip, rather than spanning the lifecycle thinly.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Medidata and Octozi are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Medidata | Octozi |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | Not recorded | 2024 |
| Headquarters | New York, New York | New York, New York, United States |
| Website | medidata.com | octozi.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Medidata its top capability grade on several axes, including Security Certifications and Trust Center, FDA and Regulatory Status and EHR and Interoperability Depth. Set against Octozi, Medidata grades higher on several axes, including Clinical and Operational Evidence, Security Certifications and Trust Center and FDA and Regulatory Status. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Octozi its top capability grade on AI Centrality and Autonomy and Oversight Model. Set against Medidata, Octozi grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Medidata or Octozi?
On the axes where the AI Health Index separates them, Medidata grades higher on several axes, including Clinical and Operational Evidence, Security Certifications and Trust Center and FDA and Regulatory Status, and Octozi grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Medidata leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Medidata and Octozi differ most?
The widest separation the AI Health Index records between Medidata and Octozi is on Security Certifications and Trust Center, where Medidata grades A and Octozi grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Medidata and Octozi grade the same?
The AI Health Index grades Medidata and Octozi the same on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Medidata and Octozi not disclosed?
At the last review, at least one of Medidata and Octozi published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
Both process sponsor trial data and neither states plainly whether one sponsor's data improves models serving another, which is the question to settle in contract before either system touches a study. Any system touching regulated trial activity carries computerised system validation obligations, and model updates inside a validated environment are not a settled matter, so ask both how updates are handled and what evidence a regulator would accept.
Medidata's AI capabilities are named rather than described, with no published oversight design. Octozi publishes no security attestation despite describing its architecture concretely. Neither publishes pricing.